# Tislelizumab as Cross-line Treatment for Advanced NSCLC

> **NCT05192681** · PHASE2 · UNKNOWN · sponsor: **Fujian Cancer Hospital** · enrollment: 35 (estimated)

## Conditions studied

- Advanced Non-small-cell Lung Cancer

## Interventions

- **DRUG:** Tislelizumab

## Key facts

- **NCT ID:** NCT05192681
- **Lead sponsor:** Fujian Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-10-10
- **Primary completion:** 2023-10-10
- **Final completion:** 2023-10-10
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2022-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05192681

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05192681, "Tislelizumab as Cross-line Treatment for Advanced NSCLC". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05192681. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*